The estimated Net Worth of Margaret Echerd is at least $526 Tisíc dollars as of 30 November 2021. Ms Echerd owns over 3,602 units of Vaxart Inc stock worth over $3,386 and over the last 13 years she sold VXRT stock worth over $0. In addition, she makes $523,068 as Sr. VP & Principal Accounting Officer at Vaxart Inc.
Ms has made over 6 trades of the Vaxart Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 3,602 units of VXRT stock worth $5,691 on 30 November 2021.
The largest trade she's ever made was exercising 47,555 units of Vaxart Inc stock on 9 June 2021 worth over $90,830. On average, Ms trades about 3,891 units every 12 days since 2011. As of 30 November 2021 she still owns at least 3,602 units of Vaxart Inc stock.
You can see the complete history of Ms Echerd stock trades at the bottom of the page.
Margaret A. Echerd is the Sr. VP & Principal Accounting Officer at Vaxart Inc.
As the Sr. VP & Principal Accounting Officer of Vaxart Inc, the total compensation of Ms Echerd at Vaxart Inc is $523,068. There are 3 executives at Vaxart Inc getting paid more, with Wouter Latour having the highest compensation of $747,711.
Ms Echerd is 62, she's been the Sr. VP & Principal Accounting Officer of Vaxart Inc since . There are 2 older and 10 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.
Margaret's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo a Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Vaxart Inc executives and other stock owners filed with the SEC include: